The Deubiquitinating Enzyme Otub2 Modulates Pancreatic Beta-Cells Function and Survival

Area of Science:

• Endocrinology
• Molecular Biology
• Cell Biology

Background:

• Ovarian tumor domain-containing ubiquitin aldehyde-binding protein 2 (Otub2), a deubiquitinating enzyme, has demonstrated anti-apoptotic effects in human islets.
• The study investigates Otub2's molecular mechanisms in regulating insulin secretion and pancreatic beta-cell function.

Purpose of the Study:

• To elucidate the role of Otub2 in insulin secretion and beta-cell function.
• To identify molecular targets and pathways regulated by Otub2 in pancreatic beta cells.

Main Methods:

• Otub2 manipulation (overexpression/silencing) in MIN6 cells and human islets.
• In vivo studies using Otub2 knockout and pancreas-specific overexpression mouse models.
• RNA sequencing and co-immunoprecipitation followed by mass spectrometry.

Main Results:

• Otub2 overexpression enhanced glucose-stimulated insulin secretion (GSIS) and inhibited NF-κB activity.
• Otub2 knockout mice showed impaired glucose tolerance and altered gene expression related to K+ transport and oxidative phosphorylation.
• Otub2 interacts with Kv9.3, Peg3, and Camk2d, proteins involved in NF-κB signaling and beta-cell apoptosis.

Conclusions:

• Otub2 is a key regulator of beta-cell function, modulating NF-κB signaling and K+ channel complexes.
• Otub2's deubiquitinating activity on Peg3 and Camk2d may protect beta cells from apoptosis and maintain insulin secretion.
• Otub2 represents a potential therapeutic target for preserving beta-cell function in diabetes.